SSI Strategy will acquire NDA Group, a leading regulatory affairs and drug development consultancy. Financial terms of the transaction were not disclosed.
This strategic combination will create a premier consultancy, specializing in guiding drug development companies from concept to commercialization, helping optimize the development process and maximize the therapeutic value of complex and novel treatments.
The merger marks an exciting milestone following years of successful collaboration across numerous clients, resulting in the launch of innovative therapies around the world.
SSI is a life sciences consultancy that has been working with clients to accelerate all stages of drug development since 2007. SSI’s core competencies include clinical development, translational medicine, clinical operations, medical affairs, pharmacovigilance, health economics and outcomes research (HEOR), and real-world evidence (RWE) services.
With a team of experts spanning the U.S. and Europe, the company works closely with drug development clients to provide an innovative and bespoke support model including embedding fully functional teams. SSI’s R&D experts and clinicians partner with clients to close gaps and achieve objectives across the drug development landscape. Founded in 1997, NDA Group has an extensive presence across the EU, UK, Switzerland, and the U.S. For over 25 years, NDA Group has provided the life science industry with unmatched regulatory expertise, ensuring that they meet the rigorous demands of the regulatory agencies. The team at NDA Group comprises more than 100 ex-regulators, industry experts and highly experienced consultants dedicated to helping drug developers make the right decisions to secure the safest and most efficient pathway to approval for their products.
Following the close of the transaction, NDA will operate as a strategic business unit (SBU) under SSI.